Alpha 2.0
Login Register
» Articles » PMID: 23022466

Haploidentical Transplantation: Repurposing cyclophosphamide

Overview
Journal Biol Blood Marrow Transplant
Date 2012 Oct 2
PMID 23022466
Citations 7
Authors
Richard J Jones
Affiliations
Soon will be listed here.
Citing Articles

Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective....

Li X, Yang J, Cai Y, Huang C, Xu X, Qiu H Front Immunol. 2023; 14:1252879.

PMID: 37954615 PMC: 10639171. DOI: 10.3389/fimmu.2023.1252879.

Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study.

Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A Leukemia. 2021; 36(3):856-864.

PMID: 34663912 PMC: 10084790. DOI: 10.1038/s41375-021-01449-1.

Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation.

Imus P, Blackford A, Bettinotti M, Luznik L, Fuchs E, Huff C Biol Blood Marrow Transplant. 2019; 25(12):2431-2437.

PMID: 31394272 PMC: 7402409. DOI: 10.1016/j.bbmt.2019.07.027.

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

Kasamon Y, Fuchs E, Zahurak M, Rosner G, Symons H, Gladstone D Biol Blood Marrow Transplant. 2018; 24(5):1022-1028.

PMID: 29353109 PMC: 5977987. DOI: 10.1016/j.bbmt.2018.01.011.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Kasamon Y, Bolanos-Meade J, Prince G, Tsai H, McCurdy S, Kanakry J J Clin Oncol. 2015; 33(28):3152-61.

PMID: 26261255 PMC: 4582145. DOI: 10.1200/JCO.2014.60.4777.